Q-omics provides the consensus-scored ARMS2 profile across patient tissues and cancer cell-line models. ARMS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARMS2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ARMS2 RNA expression shows 7,009 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, KIRC, and STAD as cancer lineages where ARMS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMS2 survival associations across molecular data types. ARMS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMS2 RNA expression–survival associations across cancer types. High ARMS2 expression shows unfavorable associations in SCLC and STAD, but favorable associations in MESO, LUAD, SKCM and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for ARMS2 RNA expression.
This table summarizes ARMS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ARMS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMS2 shows lower tumor expression in BRCA, READ and KICH and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher ARMS2 RNA expression in tumor versus normal tissue (log2 FC = +0.113, t-test p < 0.001).
This table shows molecular features associated with ARMS2 in patient tissues and cancer cell lines. In patient samples, ARMS2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ARMS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OVARY.
